Cytosorbents Corp Files 8-K on Financials
Ticker: CTSO · Form: 8-K · Filed: May 9, 2024 · CIK: 1175151
| Field | Detail |
|---|---|
| Company | Cytosorbents CORP (CTSO) |
| Form Type | 8-K |
| Filed Date | May 9, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Cytosorbents filed an 8-K detailing financial results and operations.
AI Summary
Cytosorbents Corporation filed an 8-K on May 9, 2024, reporting on its results of operations and financial condition, and including financial statements and exhibits. The filing details the company's financial performance and provides updated information regarding its business operations.
Why It Matters
This filing provides investors with crucial updates on Cytosorbents Corporation's financial health and operational performance, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- Cytosorbents Corporation (company) — Registrant
- May 9, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-36792 (company_id) — Commission File Number
- 98-0373793 (company_id) — I.R.S. Employer Identification No.
- 305 College Road East Princeton, New Jersey 08540 (address) — Principal executive offices
FAQ
What specific financial information is being reported in this 8-K?
The 8-K reports on the 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K filing made?
The filing was made on May 9, 2024.
What is the company's state of incorporation?
The company is incorporated in Delaware.
What is the principal executive office address for Cytosorbents Corporation?
The principal executive offices are located at 305 College Road East, Princeton, New Jersey 08540.
What is the Commission File Number for Cytosorbents Corporation?
The Commission File Number is 001-36792.
Filing Stats: 507 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-05-09 17:23:00
Key Financial Figures
- $0.001 — e on which registered common stock, $0.001 par value CTSO The Nasdaq Stock Marke
Filing Documents
- tm2414028d1_8k.htm (8-K) — 25KB
- tm2414028d1_ex99-1.htm (EX-99.1) — 85KB
- image_001.jpg (GRAPHIC) — 17KB
- 0001104659-24-059457.txt ( ) — 316KB
- ctso-20240509.xsd (EX-101.SCH) — 3KB
- ctso-20240509_lab.xml (EX-101.LAB) — 33KB
- ctso-20240509_pre.xml (EX-101.PRE) — 22KB
- tm2414028d1_8k_htm.xml (XML) — 3KB
02
Item 2.02 Results of Operation and Financial Condition On May 9, 2024, CytoSorbents Corporation (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2024. A copy of the press release is furnished herewith as Exhibit 99.1.*
01
Item 9.01 Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release of the Company, dated May 9, 2024 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) * The information in Item 2.02 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 9, 2024 CYTOSORBENTS CORPORATION By: /s/ Dr. Phillip P. Chan Name: Dr. Phillip P. Chan Title: Chief Executive Officer